Compounds and methods of treating infections

1. A method of treating or preventing a bacterial infection or colonisation in a subject comprising administering a therapeutically effective amount of a compound selected from the group consisting of: 2,2′-bis[(2-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL022); 2,2′-bis[(3-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL023); 2,2′-bis[(2-cyanophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL025); 2,2′-bis[(3-cyanophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL026); 2,2′-bis[(3-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL029); 2,2′-bis {[3-(trifluoromethyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (NCL037); 2,2′-bis[(2-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL039); 2,2′-bis[(3-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL040); 2,2′-bis{1-[4-(trifluoromethyl)phenyl]ethylidene}carbonimidic dihydrazide hydrochloride (NCL061); 2-{[1-(4-trifluoromethyl)phenyl]ethylidene}carbonimidic dihydrazide hydrochloride (NCL073); 2-[(4-chlorophenyl)methylene]-2′-[(4-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL076); 2-{[2-fluoro-4-(trifluoromethyl)phenyl]methylene}-2′-[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL078); 2-[(4-chlorophenyl)methylene]-2′-[(4-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL079); 2-{1-[4-(trifluoromethyl)phenyl]ethylidene}-2′-[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL080); 2-[(2-fluoro-4-chlorophenyl)methylene]-2′-[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL084); 2-[(2-cyanophenyl)methylene]-2′-[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL085); 2-[(3-cyanophenyl)methylene]-2′-[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL086); 2-[(2-fluorophenyl)methylene]-2′-[(4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL088); 2-[1-(4-chlorophenyl)ethylidene]-2′-{1-[4-(trifluoromethyl)phenyl]ethylidene}carbonimidic dihydrazide hydrochloride (NCL089); N-benzoyl-1-benzoyl-2-[(2-chlorophenyl)methylene]hydrazinecarboximidamide hydrochloride (NCL090); 2,2′-bis(cyclohexylmethylene)carbonimidic dihydrazide hydrochloride (NCL094); 2,2′-bis(3-furanylmethylene)carbonimidic dihydrazide hydrochloride (NCL095); 2,2′-bis[(3,4,5-trihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL097); 2,2′-bis[(3-carboxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL098); 2,2′-bis {[4-(1,1-dimethylethyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (NCL099); 2,2′-bis[(2,3-dihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL101); 2,2′-bis[(2,4,5-trihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL104); 2,2′-bis[(2,3,4-trihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL105); 2,2′-bis[(4,5-dihydroxy-3-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL106); 2,2′-bis[(3-hydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL108); 2,2′-bis[(3,4-dihydroxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL111); 2,2′-bis([1,1′-biphenyl]-4-ylmethylene)carbonimidic dihydrazide hydrochloride (NCL112); 2,2′-bis[(3,5-dichlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL114); 2,2′-bis[(3,4-dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL115); 2,2′-bis([1,1′-biphenyl]-2-ylmethylene)carbonimidic dihydrazide hydrochloride (NCL116); 2,2′-bis[(2,5-fluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL118); 2,2′-bis[(4-acetamidophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL119); 2,2′-bis[(4-propylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL121); 2,2′-bis [(4-hydroxy-3-nitrophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL122); 2,2′-bis[(3,4-difluorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL123); 2,2′-bis[(2-hydroxy-1-naphthalenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL124); 2,2′-bis[(3-hydroxy-4-methoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL125); 2,2′-bis[(3-ethynylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL126); 2,2′-bis[(3-bromo-4,5-dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL130); 2,2′-bis[(3-bromophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL131); 2,2′-bis[(4-chloro-6-fluoro-2H-1-benzopyran-3-yl)methylene]carbonimidic dihydrazide hydrochloride (NCL132); 2,2′-bis[(4-bromo-2-furanyl)methylene]carbonimidic dihydrazide hydrochloride (NCL133); 2,2′-bis[(2-bromo-4, 5-dimethoxyphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL135); 2,2′-bis[(4-butylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL136); 2,2′-bis[(2,6-dichlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL137); 2,2′-bis(2,3-diphenyl-2-propenylidene)carbonimidic dihydrazide hydrochloride (NCL138); 2,2′-bis(3-quinolinylmethylene)carbonimidic dihydrazide hydrochloride (NCL139); 2,2′-bis{[4-(methylsulfanyl)phenyl]methylene) carbonimidic dihydrazide hydrochloride (NCL140); 2,2′-bis[(5-chlorobenzo[b]thien-3-yl)methylene]carbonimidic dihydrazide hydrochloride (NCL141); 2,2′-bis[(5-bromo-2-furanyl)methylene]carbonimidic dihydrazide hydrochloride (NCL144); 2,2′-bis[(5-chloro-2-furanyl)methylene]carbonimidic dihydrazide hydrochloride (NCL145); 2,2′-bis(1H-indol-5-ylmethylene)carbonimidic dihydrazide hydrochloride (NCL146); 2,2′-bis(2-quinoxalinylmethylene)carbonimidic dihydrazide hydrochloride (NCL147); 2,2′-bis {[4-(carboxypropenyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (NCL148); 2,2′-bis[3-(4-methoxylphenyl)-2-propenylidene]carbonimidic dihydrazide hydrochloride (NCL150); 2,2′-bis[(2-hydroxy-3-methylphenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL152); 2,2′-bis[1-(4-chlorophenyl)propylidene]carbonimidic dihydrazide hydrochloride (NCL153); 2,2′-bis[1-(4-chlorophenyl)pentylidene]carbonimidic dihydrazide hydrochloride (NCL154); 2,2′-bis[1-(4-chlorophenyl)butylidene]carbonimidic dihydrazide hydrochloride (NCL156); 2,2′-bis[(2-amino-4-chlorophenyl)methylene]carbonimidic dihydrazide hydrochloride (NCL157); 2,2′-bis[1-(2-hydroxy-4-chlorophenyl)propylidene]carbonimidic dihydrazide hydrochloride (NCL158); 2,2′-bis[(2-hydroxy-4-chlorophenyl)(cyclopentyl)methylene]carbonimidic dihydrazide hydrochloride (NCL159); 2,2′-bis[1-(4-piperazinylphenyl)ethylidene]carbonimidic dihydrazide hydrochloride (NCL161); 2,2′-bis[1-(2-amino-4-chlorophenyl)ethylidene]carbonimidic dihydrazide hydrochloride (NCL164); 2,2′-bis(1-phenyl-2-aminoethylidene)carbonimidic dihydrazide trihydrochloride (NCL165); 2,2′-bis{[4-(trifluoromethylsulfanyl)phenyl]methylene}carbonimidic dihydrazide hydrochloride (NCL166); 2,2′-bis(phenylcarboxymethylene)carbonimidic dihydrazide hydrochloride (NCL167); 2,2′-bis {[2-(1-hydroxyethylamino)-4-chlorophenyl]methylene}carbonimidic dihydrazide hydrochloride (NCL168); 2,2′-bis[(2-amino-4-chlorophenyl)methylene]carbonimidic dihydrazide (NCL169); 2,2′-bis[(2-acetamido-4-chlorophenyl)methylene]carbonimidic dihydrazide (NCL170); 2,2′-bis{[4-(dimethylamino)-2-hydroxyphenyl]methylene}carbonimidic dihydrazide (NCL171); 2,2′-Bis[1-(2-pyridinyl)ethylidene]Carbonimidic dihydrazide hydrochloride (NCL172); 2,2′-bis[1-(4-chloro-2-hydroxyphenyl)ethylidene]carbonimidic dihydrazide hydrochloride (NCL173); 2,2′-bis(4-chloro-2-hydroxyphenylmethylene)carbonimidic dihydrazide hydrochloride (NCL174); 2,2′-Bis(2-aminopyridin-3-ylmethylene)Carbonimidic dihydrazide hydrochloride (NCL176); 2,2′-bis[1-(4-chlorophenyl)-2-hydroxyethylidene]carbonimidic dihydrazide hydrochloride (NCL177); (E)-2-(1-(4-chlorophenyl)pentylidene)hydrazine-1-carboximidamide hydrochloride (NCL188); (Z)-2-(1-(4-chlorophenyl)-2-hydrazinylethylidene)hydrazine-1-carboximidamide hydrochloride (NCL190); 2,2′-bis[1-(4-chloro-2-fluorophenyl)ethylidene]carbonimidic dihydrazide hydrochloride (NCL215); N′,2-bis((E)-4-chloro-2-fluorobenzylidene)hydrazine-1-carboximidhydrazide hydrochloride (NCL216); N′,2-bis((E)-1-(p-tolyl)ethylidene)hydrazine-1-carboximidhydrazide hydrochloride (NCL217); 2,2′-bis{1-[4-(t-butyl)phenyl]ethylidene}) carbonimidic dihydrazide hydrochloride (NCL219); 2-((E)-4-chlorobenzylidene)-1-((E)-N′-((E)-4-chlorobenzylidene)carbamohydrazonoyl)-N-ethylhydrazine-1-carboxamide (NCL226); N-benzyl-2-((E)-4-chlorobenzylidene)-1-((E)-N′-((E)-4-chlorobenzylidene)carbamohydrazonoyl)hydrazine-1-carboxamide (NCL227); 2-((E)-4-chlorobenzylidene)-1-((E)-N′-((E)-4-chlorobenzylidene)carbamohydrazonoyl)-N-hexylhydrazine-1-carboxamide (NCL228); and 2-((E)-4-chlorobenzylidene)-1-((E)-N′-((E)-4-chlorobenzylidene)carbamohydrazonoyl)-N-(furan-2-ylmethyl)hydrazine-1-carboxamide (NCL229).

2. The method according to claim 1 , wherein the bacteria causing the bacterial infection or colonisation is:

a) Gram-positive; and/or

b) selected from the group comprising: Staphylococcus aureus, Staphylococcus pseudintermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecium, Enterococcusfaecalis , and Clostridium difficile.

3. The method according to claim 1 , wherein the bacteria causing the bacterial infection or colonisation is:

a) Gram-negative; and/or

b) selected from the group comprising: Acinetobacter species, Aeromonas hydrophila, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Pseudomonas aeruginosa, Neisseria species and Stenotrophomonas maltophilia.

4. The method according to claim 1 , wherein the bacteria causing the bacterial infection or colonisation:

a) has no cell wall; and/or

b) is selected from the group comprising: Mycoplasma spp, Mycoplasma agalactiae, Mycoplasma alkalescens, Mycoplasma amphoriforme, Mycoplasma arginini, Mycoplasma bovigenitalum, Mycoplasma bovirhinis, Mycoplasma bovis, Mycoplasma bovoculi, Mycoplasma buccale, Mycoplasma californicum, Mycoplasma canadense, Mycoplasma capricolum subsp. Capricolum, Mycoplasma capricolum subsp. Capripneumoniae, Mycoplasma conjunctivae, Mycoplasma cynos, Mycoplasma dispar, Mycoplasma equigenitalium, Mycoplasma faucium, Mycoplasma felis, Mycoplasma fermentans ( incognitus str.), Mycoplasma gallisepticum (MG), Mycoplasma gateae, Mycoplasma genitalium, Mycoplasma haemocanis, Mycoplasma haemofelis, Mycoplasma haemosuis (formerly Eperythrozoon suis ), Mycoplasma hominis, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Mycoplasma hyosynoviae, Mycoplasma iowae meleagridis (MM), Mycoplasma iowae, Mycoplasma leachii, Mycoplasma lipophilum, Mycoplasma meleagridis, Mycoplasma mycoides subsp capri, Mycoplasma mycoides subsp mycoides, Mycoplasma mycoides subsp. Mycoides (such as Contagious bovine pleuropneumonia CBPP), Mycoplasma orale, Mycoplasma ovipneumoniae, Mycoplasma ovis, Mycoplasma penetrans, Mycoplasma pirum, Mycoplasma pneumoniae, Mycoplasma primatum, Mycoplasma putrefaciens, Mycoplasma salivarium, Mycoplasma spermatophilum, Mycoplasma suis, Mycoplasma synoviae (MS), Mycoplasma wenyonii, Mycoplasma, Ureaplasma spp, Ureaplasma parvum, Ureaplasma urealyticum, Ureaplasma , and Ureoplasma diversum.

5. The method according to claim 1 , wherein the infection or colonisation is caused by a mixture of at least two bacteria selected from the group comprising: Gram-positive bacteria, Gram-negative bacteria, and bacteria with no cell wall.

6. The method of claim 1 , further comprising administering a compound that reduces the integrity of the cell wall of the bacteria causing the bacterial infection or colonisation.

7. The method of claim 1 , wherein the subject is an animal selected from the group comprising human, canine, feline, bovine, ovine, caprine, porcine, avian, piscine, and equine species.

8. The method of claim 1 , wherein the compound is administered to the subject in a dose in the range of 0.1 mg/kg to 250 mg/kg bodyweight.

9. The method of claim 1 , wherein the compound is administered to the subject by oral administration, parenteral administration or topical administration.

10. The method according to claim 1 , wherein the compound is selected from the group consisting of: NCL040; NCL078; NCL079; NCL080; NCL084; NCL088; NCL089; NCL097; NCL099; NCL123; NCL146; NCL157; NCL158; NCL177; NCL188; NCL216; NCL217; and NCL219.

11. The method according to claim 1 , wherein the compound is selected from the group consisting of: NCL078; NCL079; NCL080; NCL084; NCL089; NCL097; NCL146; NCL157; NCL158; NCL177; NCL188; NCL216; NCL217; and NCL219.

12. The method according to claim 1 , wherein the compound is selected from the group consisting of: NCL089; NCL097; NCL146; NCL157; NCL158; NCL177; NCL216; NCL217; and NCL219.

13. The method according to claim 1 , wherein the compound is selected from the group consisting of: NCL089; NCL097; NCL146; NCL157; NCL158; NCL177; NCL188; NCL216; NCL217; and NCL219.

14. The method according to claim 1 , wherein the compound is selected from the group consisting of: NCL146; NCL157; NCL158; NCL177; NCL216; NCL217; and NCL219.

15. A method of treating or preventing a bacterial infection or colonisation in a subject comprising administering a therapeutically effective amount of a compound selected from the group consisting of: 4,6-bis(2-((E)-1-(4-chlorophenyl)ethylidene)hydrazinyl)pyrimidine (NCL178); 4,6-bis(2-((E)-4-chlorobenzylidene)hydrazinyl)pyrimidin-2-amine (NCL179); (2Z,2′Z)-2,2′-(pyrimidine-4,6-diylbis(hydrazin-2-yl-1-ylidene))bis(2-(4-chlorophenyl)ethan-1-ol) (NCL180); 4,6-bis(2-((E)-4-chlorobenzylidene)hydrazinyl)pyrimidine (NCL181); N4,N6-bis(1-phenylethyl)pyrimidine-4,6-diamine (NCL183); N4,N6-bis(1-phenylethyl)pyrimidine-2,4,6-triamine (NCL184); 4,6-bis(2-((E)-1-(4-chlorophenyl)ethylidene)hydrazinyl)pyrimidine hydrochloride (NCL185); 4,6-bis(2-((E)-4-chlorobenzylidene)hydrazinyl)pyrimidine hydrochloride (NCL187); (2Z,2′Z)-2,2′-(pyrimidine-4,6-diylbis(hydrazin-2-yl-1-ylidene))bis(2-(4-chlorophenyl)ethan-1-ol) hydrochloride (NCL189); 4,6-bis(2-((E)-4-bromobenzylidene)hydrazinyl)pyrimidin-2-amine (NCL193); N′,N′″-(2-aminopyrimidine-4,6-diyl)di(benzohydrazide) (NCL194); 4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine (NCL195); 4,4′-((1E,1′E)-((2-aminopyrimidine-4,6-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))diphenol (NCL196); 3,3′-((1E,1′E)-((2-aminopyrimidine-4,6-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))diphenol (NCL197); 4,6-bis(2-((E)-4-(tert-butyl)benzylidene)hydrazinyl)pyrimidin-2-amine dihydrochloride (NCL198); 4,6-bis(2-((E)-benzylidene)hydrazinyl)pyrimidin-2-amine (NCL199); 4,6-bis(2-((E)-4-(tert-butyl)benzylidene)hydrazinyl)pyrimidin-2-amine (NCL200); 4,4′-((1E,1′E)-((2-aminopyrimidine-4, 6-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))bis(N,N-dimethylaniline) (NCL201); 2,2′-((1E,1′E)-((2-aminopyrimidine-4,6-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))diphenol (NCL202); 4,6-bis(2-((E)-cyclohexylmethylene)hydrazinyl)pyrimidin-2-amine dihydrochloride (NCL203); 4,6-bis(2-((E)-1-(4-chlorophenyl)ethylidene)hydrazinyl)pyrimidin-2-amine (NCL204); 4,6-bis(2-((E)-2-chlorobenzylidene)hydrazinyl)pyrimidin-2-amine (NCL205); 4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)-1,3,5-triazin-2-amine (NCL206); 2,2′-((1E,1′E)-((6-amino-1,3,5-triazine-2,4-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))diphenol (NCL207); 4,6-bis(2-((E)-1-(4-chlorophenyl)ethylidene)hydrazinyl)-1,3,5-triazin-2-amine (NCL208); 3,3′-((1E,1′E)-((6-amino-1,3,5-triazine-2,4-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))diphenol (NCL209); 4,6-bis(2-((E)-4-(trifluoromethyl)benzylidene)hydrazinyl)-1,3,5-triazin-2-amine (NCL210); 4,4′-((1E,1′E)-((6-amino-1,3,5-triazine-2,4-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))diphenol (NCL211); 4,6-bis(2-((E)-4-bromobenzylidene)hydrazinyl)-1,3,5-triazin-2-amine (NCL212); 4,6-bis(2-((E)-cyclohexylmethylene)hydrazinyl)-1,3,5-triazin-2-amine (NCL213); 4-((E)-(2-(2-amino-6-(2-((E)-4-((diethoxyphosphoryl)oxy)benzylidene)hydrazinyl)pyrimidin-4-yl)hydrazono)methyl)phenyl diethyl phosphate (NCL218); 4,6-bis(2-((E)-4-fluorobenzylidene)hydrazinyl)pyrimidin-2-amine (NCL220); 4,6-bis(2-((E)-4-(trifluoromethyl)benzylidene)hydrazinyl)pyrimidin-2-amine (NCL221); 4,6-bis(2-((E)-3,4-difluorobenzylidene)hydrazinyl)pyrimidin-2-amine (NCL222); N,N′-(((1E,1′E)-((2-aminopyrimidine-4, 6-diyl)bis(hydrazin-2-yl-1-ylidene))bis(methanylylidene))bis(4,1-phenylene))diacetamide (NCL223); and 4,6-bis(2-((E)-4-methoxybenzylidene)hydrazinyl)pyrimidin-2-amine (NCL230).

16. The method according to claim 15 , wherein the bacteria causing the bacterial infection or colonisation is:

c) Gram-positive; and/or

d) selected from the group comprising: Staphylococcus aureus, Staphylococcus pseudintermedius, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecium, Enterococcusfaecalis , and Clostridium difficile.

17. The method according to claim 15 , wherein the bacteria causing the bacterial infection or colonisation is:

c) Gram-negative; and/or

d) selected from the group comprising: Acinetobacter species, Aeromonas hydrophila, Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella pneumoniae, Morganella morganii, Pseudomonas aeruginosa, Neisseria species and Stenotrophomonas maltophilia.

18. The method compound according to claim 15 , wherein the bacteria causing the bacterial infection or colonisation:

c) has no cell wall; and/or

d) is selected from the group comprising: Mycoplasma spp, Mycoplasma agalactiae, Mycoplasma alkalescens, Mycoplasma amphoriforme, Mycoplasma arginini, Mycoplasma bovigenitalum, Mycoplasma bovirhinis, Mycoplasma bovis, Mycoplasma bovoculi, Mycoplasma buccale, Mycoplasma californicum, Mycoplasma canadense, Mycoplasma capricolum subsp. Capricolum, Mycoplasma capricolum subsp. Capripneumoniae, Mycoplasma conjunctivae, Mycoplasma cynos, Mycoplasma dispar, Mycoplasma equigenitalium, Mycoplasma faucium, Mycoplasma felis, Mycoplasma fermentans ( incognitus str.), Mycoplasma gallisepticum (MG), Mycoplasma gateae, Mycoplasma genitalium, Mycoplasma haemocanis, Mycoplasma haemofelis, Mycoplasma haemosuis (formerly Eperythrozoon suis ), Mycoplasma hominis, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Mycoplasma hyosynoviae, Mycoplasma iowae meleagridis (MM), Mycoplasma iowae, Mycoplasma leachii, Mycoplasma lipophilum, Mycoplasma meleagridis, Mycoplasma mycoides subsp capri, Mycoplasma mycoides subsp mycoides, Mycoplasma mycoides subsp. Mycoides, Mycoplasma orale, Mycoplasma ovipneumoniae, Mycoplasma ovis, Mycoplasma penetrans, Mycoplasma pirum, Mycoplasma pneumoniae, Mycoplasma primatum, Mycoplasma putrefaciens, Mycoplasma salivarium, Mycoplasma spermatophilum, Mycoplasma suis, Mycoplasma synoviae (MS), Mycoplasma wenyonii, Mycoplasma, Ureaplasma spp, Ureaplasma parvum, Ureaplasma urealyticum, Ureaplasma , and Ureoplasma diversum.

19. The method according to claim 15 , wherein the infection or colonisation is caused by a mixture of at least two bacteria selected from the group comprising: Gram-positive bacteria, Gram-negative bacteria, and bacteria with no cell wall.

20. The method of claim 15 , further comprising administering a compound that reduces the integrity of the cell wall of the bacteria causing the bacterial infection or colonisation.

21. The method of claim 15 , wherein the subject is an animal selected from the group comprising human, canine, feline, bovine, ovine, caprine, porcine, avian, piscine, and equine species.

22. The method of claim 15 , wherein the compound is administered to the subject in a dose in the range of 0.1 mg/kg to 250 mg/kg bodyweight.

23. The method of claim 15 , wherein the compound is administered to the subject by oral administration, parenteral administration or topical administration.

24. The method compound according to claim 15 , wherein the compound is selected from the group consisting of: NCL179, NCL193, NCL195, NCL196, NCL197, NCL199, NCL202, NCL204, NCL205, and NCL221.

25. The method compound according to claim 15 , wherein the compound is selected from the group consisting of: NCL179, NCL193, NCL195, NCL197, NCL202, NCL204, NCL205, and NCL221.